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Human T-cell leukemia virus -1 (HTLV-1) is a delta
retrovirus that infects an estimated 15-25 million people
worldwide. HTLV-1 is the causative infectious agent of
adult T-cell leukemia/lymphoma (ATL) and a neurode-
generative disease (HAM/TSP). While the probability of
presenting any symptoms related to HTLV-1 infection is
relatively low (roughly 5-10% for the lifetime of an
infected individual), the disease progression and prog-
nosis of those infected individuals who develop ATL is
fatal, with a median survival range of 8-10 months.
Unfortunately, ATL is highly chemotherapy resistant
and while many current therapies improve ATL patient
survival, the patients consistently relapse. Therefore, a
need exists to develop treatments that improve ATL
outcome. We have recently identified PRMT5 (protein
arginine methyltransferase 5) as a potential target to
modulate HTLV-1 gene expression. We find that
PRMT5 protein levels are elevated in T-cell leukemia/
lymphoma cell lines compared to freshly isolated naïve
T-cells. PRMT5 RNA levels do not correlate to PRMT5
protein levels, suggesting a possible post-transcriptional
method of regulation. Furthermore, we also show that
PRMT5 protein expression is slightly elevated during
short-term immortalization, but gains highest expression
after transformation and IL-2 independence. Utilizing
shRNA vectors, we demonstrate that knockdown of
endogenous PRMT5 results in a decrease in viral p19
production in a HTLV-1-transformed cell line. Finally,
we observe a decrease in cell proliferation and in viral
gene expression when HTLV-1-infected/-transformed
cells are treated with a novel small molecule inhibitor of
PRMT5. In conclusion, we find PRMT5 to be a positive
regulator of HTLV-1 gene expression.
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